ArticleOpen medicine (Warsaw, Poland)2026
A novel prognostic model based on Golgi apparatus-related genes predicts patient survival in glioblastoma.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Glioblastoma (GBM) is a highly aggressive brain cancer. Golgi dysfunction plays a role in tumorigenesis. Methods: This study analyzed the role of Golgi apparatus-related genes (GARGs) in GBM using bioinformatics. Prognostic genes were identified using differential expression, Cox, and Lasso analyses. A prognostic model and nomogram were constructed based on gene expression and clinical characteristics. Immune infiltration and drug sensitivity analyses were performed in different risk groups. Reverse transcription quantitative PCR (RT-qPCR) was employed to explore the expression of prognostic genes. Results: A total of 5 prognostic genes (CD14, FMOD, LGR6, SLC16A13, and KDELR2) of GBM were identified, and on the basis of the prognostic genes, a prognostic model was built. There was a significant survival difference between patients in the high and low risk groups for GBM. Receiver operating characteristic (ROC) curve indicated that the predictive effect of the prognostic model in the training set was moderate, with an AUC value of around 0.7. The nomogram showed that risk score had a better predictive effect than age. Drug sensitivity analysis demonstrated that sorafenib was more sensitive in the low-risk group of GBM. RT-qPCR results revealed that compared with the control group, the expression levels of CD14 and SLC16A13 were significantly downregulated in GBM cell lines, while FMOD and LGR6 were markedly upregulated. The expression of KDELR2 exhibited obvious cell line-dependent variation. Conclusions: In summary, this study establishes a Golgi apparatus-related gene signature that not only offers prognostic insights but may also informs tailored therapeutic strategies for GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.